Introduction and aim: Methotrexate (Mtx) is an antineoplastic and immunosuppressive drug that may cause hepatotoxicity, whereas molsidomine (Mol) is a vasodilating and antioxidant agent. This study aimed to investigate the potential protective effects of Mol in Mtx-induced liver toxicity in rats. Materials and methods: Forty Wistar albino rats were equally divided into five groups: control, Mol, Mtx, Mol–Mtx, and Mtx–Mol. Following treatment, the animals were sacrificed, and liver tissue samples were histopathologically evaluated using Roening grading and Bcl-2 antibody staining. Tissue oxidants, antioxidants, and serum transaminases were measured and statistically compared across all groups. Results: No hepatic fibrosis or steatosis was observed in any of the groups. In the Mtx group, grade 2 liver injury and score 2 Bcl-2 antibody staining were observed; however, in the Mol–Mtx group, these were lower (grade 1, score 1). There were no statistically significant differences in serum transaminase levels among groups. Malondialdehyde levels were higher in all rats that received Mtx, but no differences in myeloperoxidase levels were observed among the groups. Levels of tissue antioxidants, including superoxide dismutase, glutathione (GSH) peroxidase (GSH-Px), and reduced GSH, were significantly higher in the Mol-treated and Mol pre-treated groups. Catalase (CAT) levels were elevated in all Mol-treated groups, but only in that group were CAT levels statistically significantly higher than in the control group. Conclusion: Our results suggest that some oxidant levels could increase following Mtx administration in the liver, possibly contributing to liver damage, whereas Mol could mitigate the histopathological and biochemical effects of hepatotoxicity. However, molecular studies are required to understand the exact mechanisms of these alterations.
Glucose homeostasis is a physiological process mediated by a variety of hormones. Fibroblast growth factor (FGF) 21 is a protein expressed in the liver, adipose tissue, muscle and pancreas and exer...
This study examined the impact of vitamin D (Vit D) treatment on oxidative stress in the brain caused by cisplatin (CP). A total of 21 Wistar Albino rats were allocated into three groups: control; CP, which received a single dose of 7 mg/kg CP on the first day; and VitD + CP (administered a single dose of 7 mg/kg CP on the first day followed by 1000 IU/mL Vit D for 7 days). The brain was removed immediately after the experiment. Biochemical oxidative stress (OSI), total antioxidant status (TAS), and total oxidant status (TOS) were calculated in left hemisphere tissue samples. In addition, measurements of pro‐inflammatory cytokines such as TNF‐α, IL‐1β, and IL‐6 were also performed in this tissue. We examined tissue samples from the right hemisphere using histological and immunohistochemical methods to detect Nrf2, HO‐1, BEC‐1, and LC3 proteins. Biochemical analyses revealed a slight increase in TOS and a slight decrease in TAS in the CP group, while in the VitD + CP group, TOS decreased slightly and TAS increased significantly. The differences between the groups were not statistically significant. Furthermore, the OSI value increased statistically significantly in the CP group, while it decreased statistically significantly in the VitD + CP group. In the cerebral cortex of the CP group, widespread degenerate neurons were observed, characterized by dark pyknotic nuclei. Furthermore, the results indicated that CP administration induced a significant increase in HO‐1 immunoreactivity, reflecting a compensatory activation of the Nrf2‐mediated antioxidant response. Moreover, Nrf2, HO‐1, and LC3 immunoreactivity were found to be significantly lower in the VitD + CP group compared to the CP group. Overall, VitD shows potential as an adjunctive agent against CP neurotoxicity, pending further mechanistic validation.